Cargando…
Clinical Significance and Role of Lymphatic Vessel Invasion as a Major Prognostic Implication in Non-Small Cell Lung Cancer: A Meta-Analysis
BACKGROUND: Lymphatic vessel invasion (LVI) exerts an important process in the progression and local spread of cancer cells. However, LVI as a prognostic factor for survival in non-small cell lung cancer (NSCLC) remains controversial. METHODOLOGY/PRINCIPAL FINDINGS: A meta-analysis of published stud...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527568/ https://www.ncbi.nlm.nih.gov/pubmed/23285161 http://dx.doi.org/10.1371/journal.pone.0052704 |
_version_ | 1782253752269406208 |
---|---|
author | Wang, Jun Wang, Baocheng Zhao, Weipeng Guo, Yan Chen, Hong Chu, Huili Liang, Xiuju Bi, Jingwang |
author_facet | Wang, Jun Wang, Baocheng Zhao, Weipeng Guo, Yan Chen, Hong Chu, Huili Liang, Xiuju Bi, Jingwang |
author_sort | Wang, Jun |
collection | PubMed |
description | BACKGROUND: Lymphatic vessel invasion (LVI) exerts an important process in the progression and local spread of cancer cells. However, LVI as a prognostic factor for survival in non-small cell lung cancer (NSCLC) remains controversial. METHODOLOGY/PRINCIPAL FINDINGS: A meta-analysis of published studies from PubMed and EMBASE electronic databases was performed to quantity the effects of LVI on both relapse-free survival and overall survival for patients with NSCLC. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were used to assess the strength of these effects. This meta-analysis included 18,442 NSCLC patients from 53 eligible studies. LVI appeared in 32.1% (median; range, 2.8% to 70.9%) of tumor samples. In all, patients with LVI were 2.48 times more likely to relapse by univariate analysis (95% CI: 1.92–3.22) and 1.73 times by multivariate analysis (95% CI: 1.24–2.41) compared with those without LVI. For the analyses of LVI and overall survival, the pooled HR estimate was 1.97 (95% CI: 1.75–2.21) by univariate analysis and 1.59 (95% CI: 1.41–1.79) by multivariate analysis. Multivariate analysis showed a risk was 91% higher for recurrence (HR = 1.91, 95% CI: 1.14–2.91) and 70% higher for mortality (HR = 1.70, 95% CI: 1.38–2.10) in LVI-positive I stage patients compared with LVI-negative I stage patients. Subgroup analyses showed similar significant adjusted risks for recurrence and death in adenocarcinomas, and a significant adjusted risk for death in studies that utilized elastic staining with or without immunohistochemistry in defining LVI. CONCLUSIONS/SIGNIFICANCE: The present study indicates that LVI appears to be an independent poor prognosticator in surgically managed NSCLC. NSCLC patients with LVI would require a more aggressive treatment strategy after surgery. However, large, well-designed prospective studies with clinically relevant modeling and standard methodology to assess LVI are required to address some of these important issues. |
format | Online Article Text |
id | pubmed-3527568 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-35275682013-01-02 Clinical Significance and Role of Lymphatic Vessel Invasion as a Major Prognostic Implication in Non-Small Cell Lung Cancer: A Meta-Analysis Wang, Jun Wang, Baocheng Zhao, Weipeng Guo, Yan Chen, Hong Chu, Huili Liang, Xiuju Bi, Jingwang PLoS One Research Article BACKGROUND: Lymphatic vessel invasion (LVI) exerts an important process in the progression and local spread of cancer cells. However, LVI as a prognostic factor for survival in non-small cell lung cancer (NSCLC) remains controversial. METHODOLOGY/PRINCIPAL FINDINGS: A meta-analysis of published studies from PubMed and EMBASE electronic databases was performed to quantity the effects of LVI on both relapse-free survival and overall survival for patients with NSCLC. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were used to assess the strength of these effects. This meta-analysis included 18,442 NSCLC patients from 53 eligible studies. LVI appeared in 32.1% (median; range, 2.8% to 70.9%) of tumor samples. In all, patients with LVI were 2.48 times more likely to relapse by univariate analysis (95% CI: 1.92–3.22) and 1.73 times by multivariate analysis (95% CI: 1.24–2.41) compared with those without LVI. For the analyses of LVI and overall survival, the pooled HR estimate was 1.97 (95% CI: 1.75–2.21) by univariate analysis and 1.59 (95% CI: 1.41–1.79) by multivariate analysis. Multivariate analysis showed a risk was 91% higher for recurrence (HR = 1.91, 95% CI: 1.14–2.91) and 70% higher for mortality (HR = 1.70, 95% CI: 1.38–2.10) in LVI-positive I stage patients compared with LVI-negative I stage patients. Subgroup analyses showed similar significant adjusted risks for recurrence and death in adenocarcinomas, and a significant adjusted risk for death in studies that utilized elastic staining with or without immunohistochemistry in defining LVI. CONCLUSIONS/SIGNIFICANCE: The present study indicates that LVI appears to be an independent poor prognosticator in surgically managed NSCLC. NSCLC patients with LVI would require a more aggressive treatment strategy after surgery. However, large, well-designed prospective studies with clinically relevant modeling and standard methodology to assess LVI are required to address some of these important issues. Public Library of Science 2012-12-20 /pmc/articles/PMC3527568/ /pubmed/23285161 http://dx.doi.org/10.1371/journal.pone.0052704 Text en © 2012 Wang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Wang, Jun Wang, Baocheng Zhao, Weipeng Guo, Yan Chen, Hong Chu, Huili Liang, Xiuju Bi, Jingwang Clinical Significance and Role of Lymphatic Vessel Invasion as a Major Prognostic Implication in Non-Small Cell Lung Cancer: A Meta-Analysis |
title | Clinical Significance and Role of Lymphatic Vessel Invasion as a Major Prognostic Implication in Non-Small Cell Lung Cancer: A Meta-Analysis |
title_full | Clinical Significance and Role of Lymphatic Vessel Invasion as a Major Prognostic Implication in Non-Small Cell Lung Cancer: A Meta-Analysis |
title_fullStr | Clinical Significance and Role of Lymphatic Vessel Invasion as a Major Prognostic Implication in Non-Small Cell Lung Cancer: A Meta-Analysis |
title_full_unstemmed | Clinical Significance and Role of Lymphatic Vessel Invasion as a Major Prognostic Implication in Non-Small Cell Lung Cancer: A Meta-Analysis |
title_short | Clinical Significance and Role of Lymphatic Vessel Invasion as a Major Prognostic Implication in Non-Small Cell Lung Cancer: A Meta-Analysis |
title_sort | clinical significance and role of lymphatic vessel invasion as a major prognostic implication in non-small cell lung cancer: a meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527568/ https://www.ncbi.nlm.nih.gov/pubmed/23285161 http://dx.doi.org/10.1371/journal.pone.0052704 |
work_keys_str_mv | AT wangjun clinicalsignificanceandroleoflymphaticvesselinvasionasamajorprognosticimplicationinnonsmallcelllungcancerametaanalysis AT wangbaocheng clinicalsignificanceandroleoflymphaticvesselinvasionasamajorprognosticimplicationinnonsmallcelllungcancerametaanalysis AT zhaoweipeng clinicalsignificanceandroleoflymphaticvesselinvasionasamajorprognosticimplicationinnonsmallcelllungcancerametaanalysis AT guoyan clinicalsignificanceandroleoflymphaticvesselinvasionasamajorprognosticimplicationinnonsmallcelllungcancerametaanalysis AT chenhong clinicalsignificanceandroleoflymphaticvesselinvasionasamajorprognosticimplicationinnonsmallcelllungcancerametaanalysis AT chuhuili clinicalsignificanceandroleoflymphaticvesselinvasionasamajorprognosticimplicationinnonsmallcelllungcancerametaanalysis AT liangxiuju clinicalsignificanceandroleoflymphaticvesselinvasionasamajorprognosticimplicationinnonsmallcelllungcancerametaanalysis AT bijingwang clinicalsignificanceandroleoflymphaticvesselinvasionasamajorprognosticimplicationinnonsmallcelllungcancerametaanalysis |